Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Lenalidomide Market

Lenalidomide Market Share

Report ID: GMI8286
Published Date: Feb 2024
Report Format: PDF

Download Free Sample

Lenalidomide Market Share

The competitive landscape of the lenalidomide industry is characterized by the presence of established pharmaceutical companies vying for market share. Key players are engaging in strategic initiatives such as mergers, acquisitions, and partnerships to strengthen their product portfolios. The companies are actively adopting a multi-pronged approaches to address the rising demand for effective lenalidomide.

Lenalidomide Market Companies

Prominent players operating in the lenalidomide industry are as mentioned below:

Accord Healthcare
Cipla
Deva Pharma
Dr. Reddy's Laboratories Ltd.
Glenmark Pharmaceuticals
Hetero
Hikma Pharmaceuticals
Lupin Limited
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Torrent Pharmaceuticals Ltd.
Viatris Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Lenalidomide industry size was worth USD 18 billion in 2023 and is set to expand at 5.1% CAGR from 2024-2032 propelled by the escalating prevalence of multiple myeloma worldwide and continuous advancements spurred by research endeavors.

The 10mg capsules segment generated USD 6.1 billion in revenue in 2023 and is projected to record substantial growth through 2032 as these capsules serve as a cornerstone in medical treatment regimens for offering patients a reliable and standardized dosage.

North America lenalidomide market accounted for a sizeable revenue share in 2023 and is expected to expand at a significant growth rate through 2032 owing to the heightened incidence rate of these diseases in comparison to other regions globally.

Some of the major lenalidomide firms are Accord Healthcare, Cipla, Deva Pharma, Dr. Reddy's Laboratories Ltd., Glenmark Pharmaceuticals, Hetero, Lupin Limited, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., and Viatris Inc., among others.